ArticleGenome medicine2009
Systems pharmacology and genome medicine: a future perspective.
Article in Genome medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 88 citations in OpenAlex.
- From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Systematic Identification of Genomic Markers for Guiding Iron Oxide Nanoparticles in Cervical Cancer Based on Translational Bioinformatics.International journal of nanomedicine · 2022Article
- Development of an adverse drug event network to predict drug toxicity.Current research in toxicology · 2020Article
- GWAS and Beyond: Using Omics Approaches to Interpret SNP Associations.Current genetic medicine reports · 2019Article
- Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.International journal of molecular sciences · 2018Article
- A linear programming computational framework integrates phosphor-proteomics and prior knowledge to predict drug efficacy.BMC systems biology · 2017Article
- Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study.Oncotarget · 2017Article
- A Multi-scale Computational Platform to Mechanistically Assess the Effect of Genetic Variation on Drug Responses in Human Erythrocyte Metabolism.PLoS computational biology · 2016Article
- Quantitative Systems Pharmacology: A Framework for Context.Current pharmacology reports · 2016Article
- Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Annual review of pharmacology and toxicology · 2016Review
- Integrating Multiscale Modeling with Drug Effects for Cancer Treatment.Cancer informatics · 2015Review
- System-level multi-target drug discovery from natural products with applications to cardiovascular diseases.Molecular diversity · 2014Article
- Towards structural systems pharmacology to study complex diseases and personalized medicine.PLoS computational biology · 2014Review
- Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.Drug discovery today · 2014Review
- Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles.Current pharmaceutical design · 2014Review
- Toward an integrated software platform for systems pharmacology.Biopharmaceutics & drug disposition · 2013Review
- Identification of immunomodulatory signatures induced by american ginseng in murine immune cells.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- CPT: Pharmacometrics and Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2012Article
- Signalogs: orthology-based identification of novel signaling pathway components in three metazoans.PloS one · 2011Article
- A network-based multi-target computational estimation scheme for anticoagulant activities of compounds.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Genome medicine uses genomic information in the diagnosis of disease and in prescribing treatment. This transdisciplinary field brings together knowledge on the relationships between genetics, pathophysiology and pharmacology. Systems pharmacology aims to understand the actions and adverse effects of drugs by considering targets in the context of the biological networks in which they exist. Genome medicine forms the base on which systems pharmacology can develop. Experimental and computational approaches enable systems pharmacology to obtain holistic, mechanistic information on disease networks and drug responses, and to identify new drug targets and specific drug combinations. Network analyses of interactions involved in pathophysiology and drug response across various scales of organization, from molecular to organismal, will allow the integration of the systems-level understanding of drug action with genome medicine. The interface of the two fields will enable drug discovery for personalized medicine. Here we provide a perspective on the questions and approaches that drive the development of these new interrelated fields.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.